Arsenite resistance in leishmania and possible drug targets / Gaganmeet Singh, K.G. Jayanarayan, Chinmoy S. Dey -- Unique characteristics of the kinetoplast DNA replication machinery provide potential drug targets in trypanosomatids / Dotan Sela [and others] -- Drugs and transporters in kinetoplastid protozoa / Scott M. Landfear -- Selective lead compounds against kinetoplastid tubulin / R.E. Morgan and K.A. Werbovetz -- Fishing for anti-leishmania drugs: principles and problems / Emanuela Handman [and others] -- Sterol 14-demethylase inhibitors for trypanosoma cruzi infections / Frederick S. Buckner -- Histone deacetylases / David Horn -- Targeting glycoproteins or glycolipids and their metabolic pathways for antiparasite therapy / Sumi Mukhopadhyay nee Bandyopadhyay and Chitra Mandal -- DNA topoisomerases of leishmania: the potential targets for anti-leishmanial therapy / Benu Brata Das, Agneyo Ganguly and Hemanta K. Majumder -- Antiparasitic chemotherapy: tinkering with the purine salvage pathway / Alok Kumar Datta, Rupak Datta and Banibrata Sen -- Searching the tritryp genomes for drug targets / Peter J. Myler -- Purine and pyrimidine metabolism in leishmania / Nicola S. Carter [and others]
Summary
If viewed globally, the parasitic diseases pose an increasing threat to human health and welfare. The diseases caused by kinetoplastid protozoan parasites like Leishmania and Trypanosoma continue as a cause of suffering for many millions of people in both tropical and subtropical regions of the world. Leishmania species are found throughout Latin America, Africa and Asia. Trypanosoma cruzi that cause Chagasa (TM) disease is endemic in Latin America, while members of Trypanosoma brucei group are found in sub-Saharan Africa. Although the past two decades has witnessed commendable research effort